MedTrace Logo

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

NCT00476008 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-08-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease (AD).

Conditions

Interventions

DRUG

Memantine

One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months

DRUG

Placebo

One tablet placebo morning and evening (BID) for 12 months

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Florida Atlantic University

    lead OTHER

Principal Investigators

  • Peter J Holland, MD · Charles E, Schmidt College of Medicine at Florida Atlantic University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476008 on ClinicalTrials.gov